B-RAF with PLX4032: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
<applet load='3og7' size=' | <applet load='3og7' size='400' color='white' frame='true' align='right' caption='BRAF kinase domain complex with PLX4032 (PDB code [[3og7]])' /> | ||
<scene name='B-RAF_with_PLX4032/Plx_4032_only/2'>PLX 4032</scene><br> | <scene name='B-RAF_with_PLX4032/Plx_4032_only/2'>PLX 4032</scene><br> | ||
<scene name='B-RAF_with_PLX4032/Atp/2'>ATP</scene><br> | <scene name='B-RAF_with_PLX4032/Atp/2'>ATP</scene><br> | ||
Latest revision as of 09:49, 3 January 2019
B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
|
PLX 4032
ATP
Wild-Type B-RAF
V600E Mutation
H-Bond Interaction Asp594 and PLX4032
Superposition overview
Superposition close up
Superposition active site
